Clinical Trial Update: Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy. [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating whether Xaliproden (SR57746A) can prevent oxaliplatin/5-FU/LV–induced neurotoxicity in metastatic colorectal cancer; the study status i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Leucovorin (folinic acid)
• OXALIPLATIN (Oxaliplatin)
• Xaliproden (Xaliproden)

Snippet

Sponsor: Sanofi | Conditions: Metastases, Colorectal Neoplasms | Phase 3 | Status: COMPLETED